Source comparison
Dosage Protocols: Cardiac-Specific vs GH-Focused
Traditional hexarelin protocols for GH release use 200–300 mcg administered 2–3 times daily on an empty stomach to maximise pituitary response. Cardioprotection requires a different structure. Research from the University of Turin Cardiovascular Lab demonstrat
This comparison does not assign a generated winner or score.
- Traditional hexarelin protocols for GH release use 200–300 mcg administered 2–3 times daily on an empty stomach to maximise pituitary response. Cardioprotection requires a different structure. Research from the University of Turin Cardiovascular Lab demonstrated that twice-daily administration at 100 mcg spaced 10–12 hours apart maintained CD36 receptor occupancy without inducing the cortisol or prolactin spikes seen at higher GH-stimulating doses.
- Timing relative to feeding matters less for cardiac outcomes than for GH protocols. CD36 activation isn't subject to the same glucose-mediated suppression that blunts pituitary GH release. You can administer hexarelin with food and retain cardioprotective activity. What does matter is consistency: receptor-mediated protection requires sustained low-level signalling rather than intermittent high peaks. Skipping doses creates gaps in AMPK activation that compromise ischemic tolerance.
- Clinical data from phase II cardiovascular trials used 100 mcg subcutaneously twice daily for periods ranging from 4 weeks to 12 weeks. Echocardiographic improvements (ejection fraction, diastolic function) appeared within 3–4 weeks and plateaued around week 8. Continuing beyond 12 weeks showed diminishing returns. Not because of receptor downregulation in cardiac tissue, but because the structural remodelling benefits (reduced fibrosis, improved capillary density) reach a ceiling determined by baseline cardiac damage severity.